SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX

Key Points

• SG Americas Securities LLC acquired a new stake of 208,456 shares in Immatics worth about $2.19 million (roughly 0.17% ownership), and institutional investors now hold about 64.41% of the company.
• Immatics beat expectations for the quarter with EPS of -$0.34 vs. -$0.48 est. and revenue of $23.0M vs. $12.18M est., but the company remains unprofitable with steep negative margins and ROE.
• Analysts show a consensus of "Moderate Buy" with an average price target of $19 (six Buys, one Hold, one Sell); notable notes include Jefferies initiating coverage with a Buy at $18 and Mizuho setting a $25 target.

SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ:IMTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 208,456 shares of the company's stock, valued at approximately $2,189,000. SG Americas Securities LLC owned about 0.17% of Immatics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in IMTX. Bank of America Corp DE grew its position in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after buying an additional 2,231 shares in the last quarter. Insigneo Advisory Services LLC bought a new stake in shares of Immatics in the 3rd quarter worth approximately $103,000. Engineers Gate Manager LP bought a new stake in shares of Immatics in the 2nd quarter worth approximately $124,000. Verition Fund Management LLC acquired a new stake in shares of Immatics during the 3rd quarter worth approximately $385,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Immatics by 8.3% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company's stock worth $406,000 after purchasing an additional 3,666 shares in the last quarter. Institutional investors own 64.41% of the company's stock.

Wall Street Analysts Forecast Growth

IMTX has been the subject of a number of recent research reports. Mizuho set a $25.00 target price on Immatics in a research note on Thursday, February 19th. Wall Street Zen raised shares of Immatics from a "sell" rating to a "hold" rating in a report on Monday, March 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Immatics in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group started coverage on shares of Immatics in a research report on Monday, March 16th. They set a "buy" rating and a $18.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $19.00.

Immatics Price Performance

Immatics stock opened at $10.35 on Friday. The business has a 50 day simple moving average of $9.84 and a 200 day simple moving average of $9.77. The company has a market capitalization of $1.39 billion, a PE ratio of -5.62 and a beta of 1.34. Immatics N.V. has a one year low of $3.30 and a one year high of $12.41.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.14. The firm had revenue of $23.00 million during the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%. Equities analysts anticipate that Immatics N.V. will post -0.72 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V. NASDAQ: IMTX is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient's immune system. Immatics' approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics' technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.